---
document_datetime: 2025-09-19 16:47:21
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/epysqli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: epysqli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8351307
conversion_datetime: 2025-12-22 16:38:50.576612
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Epysqli

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/09/2025                          |                                             | SmPC, Annex                      | To update Section 4.4 of the SmPC, Annex IID, and |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287199                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.4 of the SmPC, Annex IID, and section 2 of the PL to update safety information including changes in terminology due to the lift of the controlled distribution requirement, inclusion of updated Meningococcal Serogroups A, C, Y, W 135 and B in vaccine, and reinforcement of the need for (re- )vaccination against all available serotypes. The change follows assessment of the same change for the reference product, Soliris (EMEA/H/C/000791/WS2125/0133). The RMP is updated accordingly.   |            |     | II and PL   | section 2 of the PL to update safety information including changes in terminology due to the lift of the controlled distribution requirement, inclusion of updated Meningococcal Serogroups A, C, Y, W 135 and B in vaccine, and reinforcement of the need for (re-)vaccination against all available serotypes. The change follows assessment of the same change for the reference product, Soliris (EMEA/H/C/000791/WS2125/0133). The RMP is updated accordingly.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000295589 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.I.b.2 Change in test procedure for active substance or starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/09/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                       | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                                                                                                                           |            |     |                        |                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000278784 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                                                                                                                                                                                                            | 12/06/2025 | N/A |                        |                                                                                                                                                                                                                                                                                                                                                         |
| Variation type IB / EMA/VR/0000264625 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted | 13/05/2025 | N/A |                        |                                                                                                                                                                                                                                                                                                                                                         |
| Variation type IB / EMA/VR/0000262966 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be                                                                                                                        | 16/04/2025 |     | SmPC, Labelling and PL | - To update sections 5.1 and 5.2 of the SmPC following assessment of the same change for the reference product, in order to update efficacy and pharmacokinetic information based on final results from study ECU-MG-303; this is a Phase 3, open- label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of |

<div style=\"page-break-after: always\"></div>

|                                       | submitted by the MAH - Accepted C.I.2.a - To update sections 5.1 and 5.2 of the SmPC following assessment of the same change for the reference product, in order to update efficacy and pharmacokinetic information based on final results from study ECU-MG-303; this is a Phase 3, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in pediatric patients with refractory generalized myasthenia gravis (gMG). - To introduce a sentence regarding polysorbate in line with QRD template. - The MAH has taken the opportunity to implement editorial changes in all languages for alignment with the reference product, to correct for typographical errors, and for alignment with   |            | eculizumab in pediatric patients with refractory generalized myasthenia gravis (gMG). - To introduce a sentence regarding polysorbate in line with QRD template.   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000245113 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a                                                                                                                                                                                                                                                                              | 27/03/2025 |                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| biological/immunological product - Accepted   |
|-----------------------------------------------|